stinglProfessor of Dermatology, Head, Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University of Vienna

M. D: University of Vienna Medical School, Vienna, Austria (05. December 1973)
Postdoctoral Training: National Institutes of Health, Bethesda MD, U. S. A. (1977-1978; 1985-1986)

Research Interests:
• immunopathogenesis of inflammatory and neoplastic skin diseases
• phenotypic and functional characterization of inflammatory-type dendritic cells
• molecular pharmacology and immunopharmacology.

Georg Stingl, M.D. is Professor and Chairman, Division of Immunology, Allergy & Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Vienna, Austria.
Dr. Stingl earned his MD from the University of Vienna Medical School in 1973. After his internship and residency training at the Department of Dermatology I of Vienna's University Medical School, he worked as a postdoctoral fellow at the Dermatology Branch of the National Cancer Institute (1977-1978) and as a guest scientist at the Laboratory of Immunology, National Institute of Allergy and Infectious Diseases (1985-1986)of the National Institutes of Health, Bethesda, MD, USA. From1978-1981 he served as Facultymember of the Department of Dermatology of Innsbruck's University Medical School and from 1981-1992 as Staff Member and Full Professor of Dermatology at the Department of Dermatology I, University of Vienna Medical School. In 1992 he assumed his current position.
Dr. Stingl's major scientific accomplishmentsinclude the discovery of Langerhans cells as immunocytes and their role as targets of physicochemical agents, drugs and HIV; the first identification of the indigenous T cell population of rodent skin; the detection of anti-FcεR1 autoantibodies in the sera of patients with chronic urticaria; the use of genetically modified melanoma cells as vaccines for patients with far advanced disease; the induction of lytic molecules on dendritic cells after stimulation with TLR7/8 ligands.
These and other findings are documented in more than 250 original publications, 200 reviews and book chapters as well as four books.
Over the years, Dr. Stingl has appeared as Guest Professor at several medical universities and as invited speaker at many symposia and conferences. He is member of the Board of several renowned scientific societies and organisations, advisory panels, scientific journals and committees.
During his career he has received several prestigious awards such as the William Montagna Award and the Stephen Rothman Award of the Society for Investigative Dermatology and the Lifetime Achievement Award of the American Skin Association. In 1999, he received the Honorary Doctorate from the Semmelweis Medical University in Budapest. He is an Honorary Member of the Society for Investigative Dermatology and the European Society for Dermatological Research. Dr. Stingl isMember of the Austrian and the German Academy of Sciences and, in 2013, has been elected Foreign Associate Member of the Institute of Medicine of the US National Academies.

Proposed PhD research projects:
1) Role of IgE Autoimmunity in the pathogenesis of bullous pemphigoid     
2) The ontogeny of innate lymphoid cells in human skin

Selected publications:

  1. Stingl, G., E. C. Wolff-Schreiner, W. J. Pichler, F. Gschnait, W. Knapp, and K. Wolff. 1977. Epidermal Langerhans cells bear Fc and C3 receptors. Nature 268: 245-246. PMID: 887158
  2. Stingl, G., F. Koning, H. Yamada, W. M. Yokoyama, E. Tschachler, J. A. Bluestone, G. Steiner, L. E. Samelson, A. M. Lew, J. E. Coligan, and et al. 1987. Thy-1+ dendritic epidermal cells express T3 antigen and the T-cell receptor gamma chain. Proc Natl Acad Sci U S A 84: 4586-4590. PMID: 2885839
  3. Fiebiger, E., D. Maurer, H. Holub, B. Reininger, G. Hartmann, M. Woisetschlager, J. P. Kinet, and G. Stingl. 1995. Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest 96: 2606-2612. PMID: 8675625
  4. Schreiber, S., E. Kampgen, E. Wagner, D. Pirkhammer, J. Trcka, H. Korschan, A. Lindemann, R. Dorffner, H. Kittler, F. Kasteliz, Z. Kupcu, A. Sinski, K. Zatloukal, M. Buschle, W. Schmidt, M. Birnstiel, R. E. Kempe, T. Voigt, H. A. Weber, H. Pehamberger, R. Mertelsmann, E. B. Brocker, K. Wolff, and G. Stingl. 1999. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. Hum Gene Ther 10: 983-993. PMID: 10223732
  5. Stary, G., C. Bangert, M. Tauber, R. Strohal, T. Kopp, and G. Stingl. 2007. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 204: 1441-1451. PMID: 17535975

Other Publications extlink